Early access program offers experimental spinal cord injury drug

This program gives eligible people with acute spinal cord injury early access to the investigational drug elezanumab before it is officially approved. A doctor must decide if the potential benefit outweighs the risks for each patient. The program is only available in certain territories and for those who do not qualify for other treatment options or clinical trials.